ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1358 National Cancer Institute Html en Gastrointestinal Complications (PDQ®)–Health Professional Version Expert-reviewed information summary about constipation, impaction, bowel obstruction, and diarrhea as complications of cancer or its treatment. The management of these problems is discussed.
complete bowel obstruction0.653864
stool0.625324
gastrointestinal tract0.642496
Oncol Nurs Forum0.609323
cancer-related diarrhea0.733825
refractory diarrhea0.683452
diarrhea management0.729396
total bowel rest0.605453
diarrhea events0.682702
bone marrow transplantation0.599048
PUBMED Abstract0.628255
octreotide acetate0.600127
bowel lumen0.596911
abdominal pain0.618725
progressive bowel obstruction0.651874
normal bowel function0.623449
bowel obstruction0.807553
Support Care Cancer0.590223
acute diarrhea0.731833
traveler’s diarrhea0.692746
regimen-related diarrhea0.681582
small bowel0.642547
somatostatin analog octreotide0.636325
depot octreotide0.600959
chemotherapy-induced diarrhea0.813859
malignant bowel obstruction0.739577
cancer care0.622581
cancer treatment-induced diarrhea0.733195
severe diarrhea0.723383
irritable bowel syndrome0.602845
patients0.752157
Clin Oncol0.637052
cancer patients0.616135
radiation-induced diarrhea0.788656
neurogenic bowel dysfunction0.61585
diarrhea0.944656
inflammatory bowel disease0.603068
bone marrow0.600992
gastrostomy tube0.601159
Nutr Clin Pract0.61137
pelvic radiation-induced diarrhea0.726181
octreotide0.694845
extraluminal bowel lesions0.625405
Delayed diarrhea0.692341
fecal impaction0.682249
et al.0.624888
Subcutaneous octreotide0.602593
CLICK HERE
1604 National Cancer Institute Html en Bladder and Other Urothelial Cancers Screening (PDQ®)–Patient Version Expert-reviewed information summary about tests used to detect or screen for bladder cancer.
red blood cells0.494369
cancer treatment0.489394
bladder cancers0.541229
urine0.494083
ongoing clinical trials0.492966
bladder urothelium0.575205
following PDQ summaries0.556519
Transitional cell carcinoma0.483769
PDQ cancer information0.750577
cancer increases0.491939
false-negative test result0.489029
bladder cancer0.812624
clinical trials0.684635
test result0.523443
special test strip0.489962
cancer information summary0.626401
clinical trial0.502183
breast cancer prevention0.514992
false-positive test result0.488801
cancer patients0.484495
latest published information0.497666
NCI’s PDQ0.51339
cancer symptoms0.50531
NCI PDQ cancer0.589485
tests0.518118
Squamous cell carcinoma0.486084
PDQ Screening0.538371
screening tests0.491835
Cancer Information Service0.53331
urothelial cancers0.536876
PDQ Bladder0.571685
Prevention Editorial Board0.549647
treatment clinical trials0.491831
National Cancer Institute0.634201
PDQ documents0.50321
cell carcinoma0.486793
new treatment0.498073
Cancer screening trials0.570719
Cancer Care page0.519283
PDQ database0.508182
risk factor0.512484
PDQ summary0.54439
cells0.496479
cancer information summaries0.541898
comprehensive cancer information0.541535
renal pelvis0.488981
cancer0.961972
Urothelial Cancers Screening0.519534
CLICK HERE
1723 National Cancer Institute Html en Cell Phones and Cancer Risk A fact sheet that outlines the available evidence regarding use of cellular/mobile telephones and cancer risk.
study participants0.44259
Self-reported cell phone0.407518
past cell phone0.400866
cell phone calls0.471967
interphone study0.417191
cell phone subscribers0.456865
brain glucose metabolism0.405692
brain tumors0.529155
case-control study0.507596
typical cell phone0.408953
radiofrequency electromagnetic radiation0.493663
radiofrequency energy exposure0.501417
cell phone service0.411175
radiofrequency energy0.823507
brain cancer0.549627
cell phone exposure0.408273
mobile phone radiation0.402738
cell phone base0.419397
mobile phone0.45428
specific absorption rate0.399693
GSM mobile phone0.393442
glucose metabolism0.4091
Brain cancer incidence0.408493
brain tumor incidence0.393633
cell phone user0.438311
study0.591826
cohort study0.434065
United States0.44975
epidemiologic studies0.488267
brain tumor risk0.390841
cell phone0.960278
cell phone technology0.436997
National Cancer Institute0.439672
long-term cell phone0.404741
cell phones0.77677
international case-control study0.404344
prospective cohort study0.39373
brain tumor0.434845
brain cancer risk0.419878
brain0.559028
regular cell phone0.406823
non-ionizing radiation0.395758
cell phone radiofrequency0.472899
cell phone users0.536299
cell phone records0.414439
et al0.586681
cancer risk0.424868
cancer0.54982
risk0.454009
CLICK HERE
1779 National Cancer Institute Html es Depresión (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del diagnóstico, evaluación y tratamiento de la depresión en adultos y niños que padecen de cáncer.
Cancer Inst Monogr0.432628
depression among0.428544
depression screening tools0.450792
adjustment disorders0.418823
Breitbart W0.449695
psychiatric complications0.429171
Massie MJ0.417743
Manual diagnóstico0.431383
Sin embargo0.431066
early depressive symptoms0.421567
Symptom Management0.420302
women with0.486443
Lloyd-Williams M0.434521
major depression0.457401
cancer care0.484374
depressive symptom0.530327
cancer patients0.968062
managing depression0.427561
Natl Cancer Inst0.494477
mental disorders0.453242
Chochinov HM0.433278
patients with0.642851
with cancer0.624444
Pain Symptom Manage0.512784
Med Lett Drugs0.432345
Akechi T0.426152
patients treated with0.419464
women with breast0.476007
American Psychiatric Association0.511308
Care Cancer0.429533
hospital anxiety0.515664
cáncer experimentarán0.417323
palliative care0.465506
with newly0.422401
Assessing depression0.439637
Cancer survival probability0.429646
Distress Thermometer0.454338
Patient With Cancer0.438222
newly diagnosed breast0.416572
Clin Oncol0.523008
Self-Rating Depression Scale0.427421
depresión subclínica0.429498
depression scale0.646561
Ravaud A0.427826
Which depression screening0.428471
Mood Evaluation Questionnaire0.417145
escala visual analógica0.428616
Lett Drugs Ther0.430932
Holland JC0.47612
CLICK HERE
1829 National Cancer Institute Html es Tratamiento de la leucemia mieloide aguda en adultos (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda en adultos.
displasia multilinaje0.472943
panmielosis aguda0.415823
clasificación fab m30.409639
clasificación fab m40.409698
Sarcoma mieloide0.405446
clasificación fab m10.409959
clasificación fab0.532219
clasificación fab m20.426424
clasificación fab m00.410206
FLT3 internal tandem0.405506
FAB M7).Leucemia mieloide0.407876
leucemia mielomonocítica aguda0.44636
linaje mixto aguda0.409505
Leucemia basofílica aguda0.420705
adults with0.404981
clasificaciones fab0.428261
PDQ Fatiga0.40748
gránulos azurófilos0.405489
Cooperative Oncology Group0.40522
Medical Research Council0.409556
características.Leucemia mieloide aguda0.413751
leucemia promielocítica aguda0.512621
leucemia mielógena aguda0.421257
leucemia linfocítica aguda0.421928
leucemia aguda0.446208
leucemia linfoblástica aguda0.418991
síndromes mielodisplásicos0.434423
internal tandem duplication0.404884
Southwest Oncology Group0.404924
precursores eritroides0.414014
acute myeloid leukemia0.447161
leucemia monoblástica aguda0.532852
La leucemia0.450537
diferenciación mieloide0.40824
leucemia megacarioblástica aguda0.50072
leucemia monocítica aguda0.603201
transcripción mieloide0.405494
clasificaciones fab m5a0.408093
PDQ Tratamiento0.410351
leucemia megacariocítica aguda0.417046
leucemia mieloblástica aguda0.541661
leucemia eritroide0.432974
características clínicas0.409864
leucemia mieloide aguda0.973753
Southwest Oncology0.405587
Oncology Group0.408557
importante componente mieloide0.404879
clasificaciones fab m6a0.412966
tratamiento.Leucemia mieloide aguda0.414418
CLICK HERE
1859 National Cancer Institute Html es Tratamiento del cáncer de hipofaringe (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de hipofaringe.
Neck Cancer Cooperative0.13741
pharyngeal cancers0.150792
Pfister DG0.13468
pyriform sinus treated0.135606
Cancer Res0.206838
Radiat Oncol Biol0.237454
DeVita VT Jr0.131516
pyriform sinus0.18629
Natl Cancer Inst0.207961
radiation therapy0.254373
Head Neck Surg0.418544
carcinoma treated with0.123784
squamous carcinoma0.207808
with surgery0.155955
Mendenhall WM0.309662
Head Neck0.426668
estadio iv0.131056
neck squamous0.149286
Parsons JT0.126343
radioterapia preoperatoria versus0.132896
sinus treated with0.147408
treated with surgery0.145993
radioterapia posoperatoria0.168742
Oral Oncol0.128712
Hendrickson FR0.131539
treatment based0.121981
Otolaryngol Head Neck0.206433
hypopharyngeal carcinomas0.157978
radiotherapy with0.12894
with poor prognosis0.124956
hypopharyngeal squamous0.152628
Spindle cell carcinoma0.12283
Clin Oncol0.138573
combined with neck0.126143
Oncol Biol Phys0.243047
combining radiotherapy with0.126277
estadio iii0.184936
radiotherapy with surgery0.128843
Treat Options Oncol0.123145
radioterapia adyuvante posoperatoria0.177283
European Organization0.12179
neck cancer0.973991
undifferentiated carcinomas0.126856
quimioterapia neoadyuvante0.630349
locally advanced0.131399
Hansen O0.125257
induction chemotherapy0.134893
neck carcinoma0.172184
squamous cell carcinoma0.867141
CLICK HERE
1887 National Cancer Institute Html es Tratamiento del carcinoma de células de Merkel (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del carcinoma de células de Merkel.
Cutan Pathol0.403221
skin cancer0.402076
critical review with0.401107
cell carcinoma showing0.404318
review with guidelines0.401112
Australian Merkel cell0.404544
Distinct merkel cell0.404503
Am Acad Dermatol0.404485
cell polyomavirus dna0.402185
Curr Opin Oncol0.401201
Cell Carcinoma Information0.404476
7th ed0.401399
Rockville Merkel Cell0.404613
ganglios linfáticos centinela0.405335
SEER Program0.402412
cell carcinoma tumors0.407605
Coit DG0.402335
into merkel cell0.405013
Seattle Cancer Care0.401199
Cancer Care Alliance0.401228
Natl Cancer Inst0.40149
Merkel tumours0.402858
patients with merkel0.422467
with cutaneous merkel-cell0.401294
Arch Dermatol0.401934
cutaneous merkel-cell carcinoma0.404932
with merkel cell0.435163
Invest Dermatol0.401806
neuroendocrine-merkel cell carcinoma0.404323
Cancer Staging Manual0.402011
patients from0.401403
Surg Oncol0.411261
Nghiem P0.404669
New York0.401702
merkel cell carcinoma0.998942
specimens from patients0.401221
Clin Oncol0.41408
Dermatol Surg0.40166
CCM recién0.401912
Carcinoma Group0.402481
cell carcinoma demographics0.418051
primary merkel0.405524
Trabecular carcinoma0.402756
American Joint Committee0.401365
merkel cell polyomavirus0.432273
cell carcinoma after0.40431
cell polyomavirus infection0.402124
merkel-cell carcinoma0.40673
from patients with0.402629
CLICK HERE
1897 National Cancer Institute Html es Tratamiento del linfoma no Hodgkin en adultos (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin en adultos.
linfáticos afectados.ampliar linfoma0.556638
TLAM extragástrico empieza0.429482
causa signos0.417964
siguientes aspectos0.411989
anticuerpos monoclonales tipo0.445884
humano tipo0.426884
estadio s0.418117
células t0.850788
líquido cefalorraquídeo0.542154
linfocitos b0.562716
presente sumario0.415398
Leucemia mieloide aguda0.412625
células cn /T0.476942
Non-Hodgkin Lymphoma0.418323
linfocitos t0.430669
Campylobacter jejuni0.413748
ósea fabrica glóbulos0.447079
ciclina d10.412001
principales tipos0.445871
espacios huecos0.457401
células cn0.541653
estadio iiie+s0.436889
células madre0.466311
adultos jóvenes0.471716
proteína tipo cinasa0.438832
estadio iv0.435605
sudores nocturnos0.53266
leucemia linfoblástica aguda0.472861
siguientes tipos0.440813
proteína alk0.412629
abdomen).ampliar linfoma0.528931
enlace drugs approved0.432641
efectos tardíos0.529479
estadio ie0.461288
Burkitt esporádico0.418236
anticuerpos igm0.417141
estadio iie0.436552
líquido incoloro0.417873
estadio iiie0.489124
sistema nervioso central0.470481
linfoma tlam0.967052
tejido linfoide0.471693
siguientes partes0.417527
granulomatosis linfomatoide0.47171
estadio iiis0.721469
almacena glóbulos0.423547
células b0.535619
siguientes pruebas0.426588
siguientes sumarios0.417246
CLICK HERE
1903 National Cancer Institute Html es Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.
siguientes procedimientos0.533869
posibles efectos tardíos0.429839
células madre0.925937
posibles factores0.42224
adultos jóvenes0.471015
estadio iv0.456127
Burkitt recién0.429453
sistema linfático.Para0.433317
faja ajustadora0.424807
gen alk0.453637
leucemia linfoblástica aguda0.499911
estadio ii0.457571
siguientes especialistas0.421884
siguientes tipos0.435023
rayos x0.42189
después.ampliar ecografía0.422758
enlace drugs approved0.552427
niño ayuda0.422955
Sudores nocturnos0.425131
ondas sonoras0.421599
células t0.997508
efectos tardíos0.61792
PDQ Efectos tardíos0.432774
líquido cefalorraquídeo0.752047
sección linfoma0.486518
Linfoma folicular tipo0.701733
linfocitos b0.461134
La terapia0.636115
encontrarlo.ampliar exploración0.423664
determinados cambios0.538253
PDQ Tratamiento0.508964
líquido incoloro0.436562
explorador tep0.424899
siguientes factores0.424861
sistema nervioso central0.543338
proteína llamada cinasa0.449366
mayores probabilidades0.423685
Non-Hodgkin Lymphoma0.486305
estadio i0.458742
tipo paniculitis0.446711
Estados Unidos0.425103
estadio iii0.456847
tejido linfoide0.449965
ósea fabrica glóbulos0.477114
almacena glóbulos0.436048
células b0.553761
Hodgkin infantil recidivante0.525837
CLICK HERE
1922 National Cancer Institute Html es Tratamiento del cáncer de próstata (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del cáncer de próstata.
paciente presente síntomas0.437409
siguientes procedimientos0.452293
dé tratamiento0.439746
estadio iv0.493208
hiperplasia prostática benigna0.97293
ecografía transrectal0.704162
pequeña cantidad0.628387
peores efectos0.412864
estadio ii0.558135
siguientes tipos0.419876
tumor dosis0.421814
rayos x0.418531
sistema urinario masculino0.436824
ondas sonoras0.422219
principal fuente0.412408
características sexuales masculinas0.423477
enlace medicamentos0.465713
National Cancer Institute0.412027
sustancia radiactiva llamada0.426571
biopsia.ampliar ecografía0.431707
Instituto Nacional0.421293
estadios iia0.418459
hormonas masculinas0.458793
PDQ Tratamiento0.424516
hormonas sexuales masculinas0.442195
estadio iia0.431816
siguientes problemas0.426176
presente sección0.409743
tejidos cercanos.A veces0.421604
Physician Data Query0.443132
posibles problemas0.411863
Estados Unidos0.4216
estadio iii0.498677
linfadenectomía pélvica0.487486
prostatectomía radical.ampliar resección0.439705
aparato reproductor masculino0.440962
siguientes sustancias0.416831
hipertrofia prostática benigna0.438255
alta intensidad0.548873
prostatectomía retropúbica0.464416
Ganas repentinas0.423669
próstata solas0.515159
siguientes pruebas0.46951
siguientes estadios0.460134
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.